Search
Sarepta Therapeutics Inc
SRPTAdd to Watchlist
18.200USD
+0.230+1.28%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.92BMarket Cap
29.21P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.28%
5 Days
+9.01%
1 Month
+3.35%
6 Months
-15.43%
Year to Date
-15.43%
1 Year
+2.77%
Key Figures
18.230Open
18.410High
3.43MVolume
29.21P/E TTM
14.85P/E Dynamic
--Dividend TTM
3.25%Turnover Ratio
17.970Prev. Close
17.450Low
45.55MTurnover
8.17P/E Static
1.28P/B
0.00%Div Yield TTM
1.96%ROA
43.91652wk High
0.51Volume Ratio
235.24MNet Profit
105.57MShares
0.6231EPS TTM
0.21Beta
4.91%ROE
10.41552wk Low
5.34%Amplitude
85.02%Gross Margin
1.92BMarket Cap
2.38Reward/Risk
4.45%Risk Rate
TradingKey Stock Score of Sarepta Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Sarepta Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 22.01.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sarepta Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Sarepta Therapeutics Inc Highlights
StrengthsRisks
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 76.80% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.20B.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 29.21, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 95.57M shares, decreasing 20.91% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 104.32K shares of this stock.
Analyst Rating
Based on
28
analysts
Hold
Current Rating
22.009
Target Price
+22.48%
Upside Space
Sarepta Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sarepta Therapeutics Inc Info
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Ticker SymbolSRPT
CompanySarepta Therapeutics Inc
CEOIngram (Douglas S)
Websitehttps://www.sarepta.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Sarepta Therapeutics Inc (SRPT)?
The current price of Sarepta Therapeutics Inc (SRPT) is 18.20.
What is the symbol of Sarepta Therapeutics Inc?
The ticker symbol of Sarepta Therapeutics Inc is SRPT.
What is the 52-week high of Sarepta Therapeutics Inc?
The 52-week high of Sarepta Therapeutics Inc is 43.92.
What is the 52-week low of Sarepta Therapeutics Inc?
The 52-week low of Sarepta Therapeutics Inc is 10.41.
What is the market capitalization of Sarepta Therapeutics Inc?
The market capitalization of Sarepta Therapeutics Inc is 1.92B.
Is Sarepta Therapeutics Inc (SRPT) currently rated as Buy, Hold, or Sell?
According to analysts, Sarepta Therapeutics Inc (SRPT) has an overall rating of signal_hold, with a price target of 22.01.
What is the Earnings Per Share (EPS TTM) of Sarepta Therapeutics Inc (SRPT)?
The Earnings Per Share (EPS TTM) of Sarepta Therapeutics Inc (SRPT) is -7.13.